Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines
about
Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cellsTargets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cellsIdentification of FGF receptor-binding peptides for cancer gene therapy.FGF receptor-mediated gene delivery using ligands coupled to polyethylenimine.Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.Vasohibin‑2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor‑2 and growth/differentiation factor‑15 expressionIdentification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties.Receptor-mediated gene delivery using polyethylenimine (PEI) coupled with polypeptides targeting FGF receptors on cells surface.Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer TherapiesThe adhesion molecule NCAM promotes ovarian cancer progression via FGFR signallingDesign and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.Perspectives in vector development for systemic cancer gene therapy.miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancerThe fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerProtein arginine methyltransferase 5 is essential for growth of lung cancer cells.Targeting RSK2 in human malignancies.Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo.In vivo anti-tumor effect of expressing p14ARF-TAT using a FGF2-targeted cationic lipid vector.The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency.Dual-targeting non-viral vector based on polyethylenimine improves gene transfer efficiency.GPC5 gene and its related pathways in lung cancer.Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells.Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer.Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells.Collagens, stromal cell-derived factor-1alpha and basic fibroblast growth factor increase cancer cell invasiveness in a hyaluronan hydrogel.Expression of FGF2Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
P2860
Q24658237-AE00DE2C-AB6C-447F-AC5B-18C49507F41BQ28575842-6BB40B84-6242-4328-963C-ECE509FAB6DDQ31063018-65102CF8-C2D4-43EE-8FCA-03ECE4B736FBQ33270434-704F8735-2B1A-4E79-82B1-AF0C49436F23Q33638206-4A7D3648-6FF6-4278-BDF3-736E195176E6Q33770265-4355312A-9A4F-4194-B648-9192C911C203Q33784827-CAAF6DC5-4F4D-4353-8CBE-1230F2AA4C30Q33891210-2B4D238A-154F-4E0C-98CB-97F96691150CQ34166436-808EE6F6-9FBE-44B8-9471-3A784D6D9C02Q35129377-88320DB8-437A-4159-878C-94A6949F7247Q35641791-44202AC5-E0BB-44B4-8DA4-CEE6F297B03BQ36038778-3765B158-3F0F-40CF-93C3-06AEDCFAA1CDQ37175328-BD21D9B0-DD5A-43E1-9BB2-1E2BE53AD2B1Q37214820-1B75D5D4-2045-451B-82A0-0C329A95C2DAQ37344496-F0EA717E-1887-4B75-81E1-94EAD5C0AC43Q37389768-83AA961B-A504-480E-A605-BF5263DC5AF4Q37398814-0F192000-8318-4E04-87B9-428825B1E584Q37802388-8982F2D7-34CB-476D-8F0A-3F47E0409FD3Q38363715-7BB7A884-29DD-4A46-A7B5-E12079ADEF8FQ39605996-3992C9A4-A011-4587-BA89-D99C364BEB2BQ39647893-13504D04-7818-4842-B871-20E41100CE35Q39975416-529B6CCF-71B7-46AA-A524-5A0FE5B960C2Q40123596-59EBF5D6-3525-4731-B444-9424AA150A88Q41786499-AFA32459-56D2-4F90-8564-80BC0B2F09A1Q43728209-5ABC5D40-F81C-46A3-BA28-02AC7462B600Q43756598-591835B8-11ED-43B3-A46D-7DAD16A994CDQ45207524-B5083346-0AE4-4787-B03B-8299B282374AQ46705812-7F208409-9E96-4BBD-95B2-5F90E7787523Q50287926-B2D4E4A0-4697-45F0-90F8-925DF4D074C8Q52862866-92FA1922-1050-4D58-A405-89A490D19710
P2860
Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines
description
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im Mai 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/05/05)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/05/05)
@nl
наукова стаття, опублікована в травні 1999
@uk
مقالة علمية (نشرت في 5-5-1999)
@ar
name
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@ast
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@en
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@nl
type
label
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@ast
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@en
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@nl
prefLabel
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@ast
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@en
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@nl
P2093
P3181
P356
P1476
Prevalent expression of fibrob ...... FGF2 in human tumor cell lines
@en
P2093
B A Sosnowski
G F Pierce
L A Chandler
L Greenlees
S L Aukerman
P304
P3181
P356
10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.0.CO;2-H
10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8
P50
P577
1999-05-01T00:00:00Z